Target intelligence / Profile preview

Dual signaling pathways in tumor development

Overview

The phrase "dual signaling pathways in tumor development" describes a phenomenon in cancer biology where key cell signaling pathways (such as TGF-β, Hippo/YAP, Wnt/β-catenin, and others) can exert context-dependent effects—acting as tumor suppressors in early cancer stages but promoting tumor progression, invasion, or metastasis at later stages through complex pathway crosstalk and regulatory mechanisms. This is not a molecular entity, receptor, protein, or gene, and thus cannot serve as a specific therapeutic target, biomarker, or drug target in itself[1][2][3].

Beyond the preview

Go deeper on Dual signaling pathways in tumor development.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dual signaling pathways in tumor development.

Explore the full profile